DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

RTTNews | Před 540 dny
Stocktwits
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.

Charles River Research Models & Services (RMS) sales and marketing teams will collaborate with DURECT to jointly market and commercialize the ALZET product line to existing and new customers over a multi-year period.

Charles River RMS will provide dedicated marketing resources and collaborate with DURECT to develop and roll out a broad range of sales and marketing initiatives for ALZET.

DURECT will remain responsible for manufacturing, marketing support, order fulfillment and customer billing.

Značky : DRRX CRL
Stocktwits
read more
Charles River Laboratories Slashes FY24 Outlook - Update

Charles River Laboratories Slashes FY24 Outlook - Update

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews | Před 384 dny
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews | Před 838 dny
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews | Před 1119 dny
DURECT Appoints Timothy Papp As New CFO

DURECT Appoints Timothy Papp As New CFO

Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews | Před 1148 dny
TSX Modestly Higher As Financials, Mining Stocks Move Up

TSX Modestly Higher As Financials, Mining Stocks Move Up

Despite concerns about global trade, and political uncertainty in Europe, the Canadian market is modestly higher Tuesday afternoon, supported by gains in materials, industrials and financials sectors.
RTTNews | Před 19 minutami
Swiss Market Settles Weak

Swiss Market Settles Weak

After opening with a big negative gap Tuesday morning, the Swiss market gradually recovered some lost ground, and even managed a brief spell in positive territory midway through the session, but failed to sustain momentum and finally ended the day's session in the red.
RTTNews | Před 37 minutami
Nástroje
Ekonomický kalendář
Otevírací hodiny trhu
Úrokové sazby
Kalendář svátků
Forexový trh
Forex volatilita
Korelace Forexu
Novinky na Forexu
Analýza forexu
COT údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Tepelná mapa indikátorů
Komunita
Komunita
Systémy
Nejpopulárnější systémy
Strategie
Soutěže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenze
Brokeři
Proprietární obchodní firmy
Služby VPS
Poskytovatelé signálu
Služby programování EA
Partnerské programy
Služby PAMM Brokera
Služby slevového programu
Obchodní platformy
Odborní poradci
Kryptoburzy
Kurzy obchodování
Brokeři
Forex Spready
Nabídky Forex brokerů
Swapy Forex brokerů
Objem brokera Forexu
Propagační akce Forex Brokera
Tisková Zpráva
Platforma
Miniaplikace
Funkce
API
RSS
Stock Portfolio
Affiliate Software
Rozšířené grafy
Podpora
Časté dotazy
Pomoc
Kontaktuj nás
Nahlásit chybu!
O nás
Blog
& copy; 2025 Myfxbook Ltd. Všechna práva vyhrazena.
UPOZORNĚNÍ NA VYSOKÉ RIZIKO: Obchodování s devizami přináší vysokou úroveň rizika, které nemusí být vhodné pro všechny investory. Páka vytváří další rizika a ztráty. Než se rozhodnete obchodovat s devizami, důkladně zvažte své investiční cíle, úroveň zkušeností a toleranci vůči riziku. Můžete přijít o část nebo všechny své počáteční investice. Neinvestujte peníze, které si nemůžete dovolit ztratit. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všechny údaje a informace jsou poskytovány "tak, jak jsou". pouze pro informační účely a nejsou určeny pro obchodní účely nebo rady. Výkonnost v minulosti neznamená výkonnost v budoucnosti.